Interim report January-September 2014: Good growth and

Third quarter:

  · Sales growth was 9 percent in local currency. Sales amounted to SEK 125
(109) million, corresponding to an increase of 15 percent in SEK. Last year’s
figure included sales of the transplantation product STEEN Solution™ to Xvivo to
the tune of SEK 3 million. Adjusted for this, the increase in sales amounted to
12 percent in local currency.
  · Operating income (EBIT) amounted to SEK 44 (23) million, corresponding to an
operating margin of 35 (21) percent.
  · Net income amounted to SEK 36 (17) million, which gave earnings per share of
SEK 1.79 (0.85).

January - September:

  · Sales growth was 10 percent in local currency. Sales amounted to SEK 374
(329) million, corresponding to an increase of 13 percent in SEK. Last year’s
figure included sales of the transplantation product STEEN Solution™ to Xvivo to
the tune of SEK 8 million. Adjusted for this, the increase in sales amounted to
12 percent in local currency.
  · Operating income (EBIT) amounted to SEK 107 (59) million, corresponding to
an operating margin of 29 (18) percent.
  · Net income amounted to SEK 81 (41) million, which gave earnings per share of
SEK 4.07 (2.06).

After the end of the period:

  · Vitrolife AB has entered into an agreement to acquire all the shares of
Unisense FertiliTech A/S, the market leader within the field of embryo
monitoring, time-lapse, for IVF.

Gothenburg, November 6, 2014
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:

Thomas Axelsson, CEO, tel 46 31 721 80 01

Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on
November 6, 2014 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife (http://www.vitrolife.com/en/Corporate/) is an international medical
device Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/)
product area develops, produces and markets medical devices for assisted
reproduction. Work is also carried out to enable the use and handling of stem
cells for therapeutic purposes

Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 250
employees and the company's products are sold in almost 110 markets. The company
is headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The
Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is
listed on NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Small Cap.

________________________________________________________________________________
_ 
________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/
Interim report January-September 2014: Good growth and considerably stronger results

Attachments
